Dr. Kavanaugh has received consulting fees, speaking fees, and/or honoraria from Centocor Ortho Biotech, now Janssen Biotech (less than $10,000) and has received funding for clinical research sponsored by Abbott, Amgen, Janssen, and UCB.
Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial†
Article first published online: 27 JUL 2012
Copyright © 2012 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 64, Issue 8, pages 2504–2517, August 2012
How to Cite
Kavanaugh, A., van der Heijde, D., McInnes, I. B., Mease, P., Krueger, G. G., Gladman, D. D., Gómez-Reino, J., Papp, K., Baratelle, A., Xu, W., Mudivarthy, S., Mack, M., Rahman, M. U., Xu, Z., Zrubek, J. and Beutler, A. (2012), Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis & Rheumatism, 64: 2504–2517. doi: 10.1002/art.34436
ClinicalTrials.gov identifier: NCT00265096.
- Issue published online: 27 JUL 2012
- Article first published online: 27 JUL 2012
- Accepted manuscript online: 29 FEB 2012 12:47PM EST
- Manuscript Accepted: 9 FEB 2012
- Manuscript Received: 31 MAR 2011
- Janssen Research & Development LLC (formerly Centocor Research and Development, a subsidiary of Johnson & Johnson)
Additional Supporting Information may be found in the online version of this article.
|ART_34436_sm_suppltable1.doc||49K||Supplementary Table 1|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.